title: Beyond chemotherapy and targeted therapy: adoptive cellular therapy in non-small cell lung cancer.
abstract: Non-small cell lung cancer (NSCLC) is an intractable disease for which effective treatment approaches are urgently needed. The ability to induce antigen-specific immune responses in patients with lung cancer has led to the development of immunotherapy as a novel concept for the treatment of NSCLC. Adoptive cellular therapy (ACT) represents an important advancement in cancer immunotherapy with the utilization of tumor infiltrating lymphocytes, cytokine-induced killer cells, natural killer cells and γδ T cells. In this study, we review recent advances in ACT for NSCLC in clinical trials and provide a perspective on the improvement in ACT and potential therapeutic approaches using engineered T cell therapy for NSCLC.
authors: Department of Immunology, Norman Bethune College of Medicine, Jilin University, Changchun, 130021, Jilin, People's Republic of China, wangjunyingjilin@gmail.com.
authors: Junying
authors: J
authors: Wang
authors: Xueju
authors: X
authors: Wang
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology / Q000628:therapy*; D055612:Cytokine-Induced Killer Cells / Q000276:immunology; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007694:Killer Cells, Natural / Q000276:immunology; D016032:Randomized Controlled Trials as Topic; D013601:T-Lymphocytes / Q000276:immunology; D016896:Treatment Outcome